Learn More
The olfactory bulb as the entry site for prion-like propagation in
neurodegenerative diseases
Learn More

Diabetes drug slows experimental Parkinson’s disease progression,
human trials to begin next year



Patrik Brundin Laboratory
Research in Patrik Brundin’s laboratory focuses on pathogenetic mechanisms and pharmacological treatment in cell and animal models of Parkinson’s disease. The group’s mission is to understand neurodegenerative diseases and develop new therapies that are of benefit
to patients and their caregivers.

Learn More

In the Press

19 Oct. 2021 | Podcast episode 115: Repurposing medications to slow progression of PD
Parkinson’s Foundation

22 March 2019 Patrik Brundin: life on the river
Adrian Burton | The Lancet

9 Oct. 2018 Linked Clinical Trials initiative boosts number of Parkinson’s clinical studies
Jose Marques Lopes, Ph.D | Parkinson’s News Today

26 Oct. 2016 Pathology: The prion principle

2 June 2015 Dutch king and queen visit children’s hospital, learn about Parkinson’s research

29 May 2015 Dutch program could make Grand Rapids a destination for Parkinson’s care


Grand Challenges in Parkinson's Disease
Grand Challenges in Parkinson's Disease

Congratulations to Dr. Ted Dawson of Johns Hopkins Medicine, the recipient of this year's Jay Van Andel Award for Outstanding...